Nanobiotix Sa ADR ( (NBTX) ) has released its Q2 earnings. Here is a breakdown of the information Nanobiotix Sa ADR presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Nanobiotix SA ADR is a clinical-stage biotechnology company based in Paris, France, specializing in innovative nanoparticle-based therapeutic approaches for cancer treatment. The company is listed on Euronext Paris and the Nasdaq Global Select Market.
In its latest earnings report for the first half of 2025, Nanobiotix highlighted significant progress in its clinical development programs, particularly focusing on its lead product candidate, JNJ-1900 (NBTXR3), for head and neck squamous cell carcinoma and non-small cell lung cancer. The company also reported a substantial increase in revenue, primarily due to a contractual amendment with Janssen Pharmaceutica.
Key financial highlights include a revenue increase to €26.6 million from €9.3 million in the same period last year, driven by a one-time revenue of €21.2 million from the Janssen agreement amendment. Operational expenses decreased to €25.8 million from €32.9 million, leading to an operating profit of €0.8 million compared to a loss of €23.7 million in the previous year. Despite this, the company reported a net loss of €5.4 million, a significant improvement from the €21.9 million loss in the first half of 2024.
Strategically, Nanobiotix has strengthened its financial position through an amended license agreement with Janssen, which transfers most financial responsibilities for the ongoing Phase 3 trial to Janssen. This amendment is expected to support the company’s financial sustainability and future growth.
Looking ahead, Nanobiotix aims to leverage potential revenues from JNJ-1900 (NBTXR3) to fund the development of its other platforms, Curadigm and Oocuity. The company remains focused on advancing its clinical programs and exploring strategic partnerships to enhance its financial stability and operational capabilities.